T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma
Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrea Anichini(Fondazione IRCCS Istituto Nazionale dei Tumori), Ilaria Bersani(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Agustoni(University of Pavia), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Di Tolla(Fondazione IRCCS Istituto Nazionale dei Tumori), Jeffrey S. Weber(NYU Langone Health), Roberta Mortarini(Scripps Research Institute), Gabrina Tragni(Tumori Foundation), Valentina Colonna(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 8
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k